Bodycote (LON:BOY) had its target price upped by equities researchers at Liberum Capital from GBX 1,025 ($13.90) to GBX 1,050 ($14.24) in a research note issued on Friday. The brokerage presently has a “buy” rating on the stock. Liberum Capital’s target price points to a potential upside of 10.35% from the company’s current price.
A number of other equities research analysts also recently issued reports on BOY. Numis Securities reiterated a “hold” rating and set a GBX 925 ($12.54) price target on shares of Bodycote in a research report on Tuesday, December 5th. reiterated a “hold” rating and set a GBX 900 ($12.21) price target on shares of Bodycote in a research report on Friday, September 29th. Peel Hunt reiterated a “buy” rating and set a GBX 965 ($13.09) price target on shares of Bodycote in a research report on Tuesday, October 31st. JPMorgan Chase & Co. restated a “neutral” rating and set a GBX 850 ($11.53) price objective on shares of Bodycote in a research report on Friday, October 27th. Finally, Beaufort Securities restated a “buy” rating on shares of Bodycote in a research report on Friday, October 27th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Bodycote presently has a consensus rating of “Buy” and an average target price of GBX 919.55 ($12.47).
Shares of Bodycote (BOY) opened at GBX 951.50 ($12.90) on Friday. Bodycote has a 12-month low of GBX 624 ($8.46) and a 12-month high of GBX 980 ($13.29). The stock has a market cap of $1,820.00 and a P/E ratio of 2,320.73.
Bodycote plc is a provider of thermal processing services. The Company has six operating segments, split between Aerospace, Defense and Energy (ADE) and Automotive and General Industrial (AGI) business areas: ADE-Western Europe; ADE-North America; ADE-Emerging markets; AGI-Western Europe; AGI-North America, and AGI-Emerging markets.
What are top analysts saying about Bodycote? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bodycote and related companies.